Dragon outside ‎⁨Kiyomizu-dera Temple⁩, ⁨Kyoto⁩

It’s time to review some key highlights from ESMO in the early stage pipeline products.

There were so many on our list this year we split the review into two parts.

One challenge many biotechs face is the decision on whether or not to present initial clinical data before the full cohort has completed enrolled.

Do they go for a quick snapshot demonstrating some activity in a truncated waterfall plot as an ‘encouraging sign’ or wait for the full picture and hope it holds up over time?

It’s interesting to see this played out every year at ESMO.

At ASH and ASCO an early look will likely end up in a poster, but at ESMO there are far more slots available for developmental therapeutics, even in tumour type oral proferred papers or mini-oral sessions.

If the reaction isn’t what you expect then it can unwittingly become an actionable event for a public company.  This comes with both blessings and a curse so choose wisely.

In this review we have a mix of small and large companies, as well as regional diversity from UK/EU, US,  and Asia…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by